OncoMatch/Clinical Trials/NCT06173999
A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
Is NCT06173999 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including SHR2554/CHOP and SHR2554/CHOEP for peripheral t-cell lymphoma.
Treatment: SHR2554/CHOP · SHR2554/CHOEP — The study is being conducted to evaluate the safety and efficacy of SHR2554 with CHOP/CHOEP in treatment- naïve peripheral T-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
No prior treatment (treatment-naive required)
Max 0 prior lines
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify